Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
Launched by FLORIDA STATE UNIVERSITY · Oct 13, 2023
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help people who regularly use cannabis and struggle with stress. The researchers want to see if a short, computer-based program can help reduce feelings of distress and lower cannabis use among those diagnosed with Cannabis Use Disorder (CUD). The program will be delivered in one session and will include reminders on a smartphone to keep participants engaged. The goal is to find out if this intervention can improve emotional coping skills and lead to less cannabis use.
To participate in this trial, individuals need to be between the ages of 65 and 74 and must be daily cannabis users with a diagnosis of CUD and high levels of distress intolerance, which means they struggle to handle negative emotions. Participants will be asked to complete a series of assessments about their cannabis use and emotional well-being. It’s important to note that individuals with serious mental health issues, those who are pregnant, or those currently receiving certain therapies or medications may not be eligible. Overall, this study aims to provide a helpful tool for those looking to manage their cannabis use and emotional challenges more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cannabis is the primary substance of abuse.
- • Clinical-level Distress intolerance Index score.
- • Current Cannabis Use Disorder diagnosis.
- • Near-daily to daily cannabis use in past-month and past 3 months.
- • Positive urine screen for THC
- • Detectable skin conductance level
- • Owns a smart phone
- • Primary smoked/vaporized delta-9 or delta-8 THC user
- Exclusion Criteria:
- • Presence of acute/major psychiatric disturbance
- • Current pregnancy
- • Change in psychotropic medication within the past month
- • Concurrently receiving treatment for cannabis use
- • Concurrently receiving dialectical behavior therapy or exposure-based therapy for emotional disorders
- • Planning to immediately quit using cannabis
- • EEG contraindications
- • Kidney disease
About Florida State University
Florida State University (FSU) is a prestigious public research institution located in Tallahassee, Florida, known for its commitment to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, FSU leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the medical community. The university fosters a collaborative environment that brings together multidisciplinary teams to design, implement, and analyze clinical studies, ensuring adherence to the highest ethical and scientific standards. Through its clinical trials, FSU aims to address critical health challenges and translate research findings into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Auburn, Alabama, United States
Tallahassee, Florida, United States
Patients applied
Trial Officials
Richard J Macatee, PhD
Principal Investigator
Florida State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported